COPD is characterized by abnormal repair in the lung resulting in airway obstruction 27 associated with emphysema and peripheral airway fibrosis. As the presence and degree of 28 airways disease and emphysema varies between COPD patients this may explain the 29 heterogeneity in the response to treatment. It is currently unknown whether and to what extent 30 inhaled steroids can affect the abnormal repair process in the airways and lung parenchyma in 31
Introduction 51
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is 52 predominantly caused by longstanding smoking. Its progression can generally not be halted 53 by currently available therapies. COPD is characterized by persistent airway obstruction. This 54 airway obstruction is, apart from changes in large airways like smooth muscle and goblet cell 55 hyperplasia, predominantly caused by peripheral airway fibrosis and inflammation in the 56 small airways and lung parenchyma, and loss of lung tissue (emphysema) (9). The molecular 57 mechanisms by which tissue breakdown and repair as well as airway fibrosis can take place in 58 one organ, the lung, are intriguing, especially so since they are caused by one common 59 etiologic factor (smoking). The presence and degree of airway fibrosis and emphysema is 60 variable between patients and may explain the heterogeneity in the response to treatment in 61 COPD patients. Therefore further insight in the underlying molecular mechanisms of tissue 62 breakdown, repair and fibrosis in COPD is needed and clinically relevant with respect to its 63 implications for improved and better targeted treatment. 64
The core effector cells involved in tissue repair and remodeling in the lung are pulmonary 65
fibroblasts, main producers of extra cellular matrix (ECM), and interstitial inflammatory cells 66 and epithelial cells, important cytokine and protease producers. A common link between these 67 cells is that they all produce but also respond to transforming growth factor beta (TGFβ), a 68 key factor in tissue repair and remodeling. TGFβ induces ECM production by pulmonary 69 fibroblasts and signals predominantly via the intracellular Smad pathway (5, 11). TGFβ plays 70 an important role in the tissue repair process in COPD (4, 11). We have previously 71 demonstrated an altered presence of the TGFβ-Smad pathway in COPD (23) as well as a 72 different regulation of the Smad pathway in pulmonary fibroblasts from patients with 73
COPD(22). 74
Next to smoking cessation, which is crucial in preventing worsening of disease, 75 bronchodilators and inhaled steroids are currently standard treatment options for patients with 76 COPD(6). None of these treatments can cure COPD, but inhaled steroids either alone or in 77 combination with bronchodilators have been shown to improve health status and respiratory 78 symptoms next to reducing frequent exacerbations (1, 2, 18, 21). Some recent studies have 79 demonstrated that inhaled steroids can also reduce the decline in lung function at least in a 80 subset of COPD patients (3, 13). 81
It is yet unclear whether and to what extent inhaled steroids can affect the abnormal repair 82 process in the airways and lung parenchyma in COPD. Given the heterogeneity in 83 involvement of airway and parenchymal changes in COPD and the seemingly contradiction of 84 increased ECM deposition in airways and loss of ECM in parenchyma, we hypothesized that 85 different lung fibroblast phenotypes exist and that steroids differentially affect fibroblasts 86 from these different locations. 87
To tackle this hypothesis we investigated the effects of fluticasone on TGFβ-and cigarette 88 smoke-induced changes in Smad signaling and ECM production in both airway and 89 parenchymal lung fibroblasts from patients with severe COPD. 
Subjects 101
Primary lung fibroblasts were freshly isolated from lung tissue of patients with severe stage 102 IV COPD, undergoing lung transplant surgery. All patients were female, had quitted smoking 103 for at least one year and were using inhaled and/or oral steroids at time of surgery. Fibroblast cultures were established by means of an explant technique as described previously 112 (15, 16). For our airway fibroblast cell cultures we start at the main stem bronchus and dissect 113 airway tissue ranging from the 3rd-5th generation. For parenchymal fibroblasts, lung tissue is 114 taken from peripheral areas of the lung with exclusion of visible blood vessels and airways. 115
There was no mycoplasma contamination in the fibroblast cultures, as confirmed by a 116 mycoplasma detection kit (Roche Diagnostics, Almere, The Netherlands). Isolated cells were 117 characterized as fibroblasts by morphological appearance and expression pattern of specific 118 proteins as described previously (16). Fibroblasts were cultured in complete culture medium 119 (Ham's F12, 10%FBS, penicillin, streptomycin and glutamin (all from Lonza, Breda, the 120 Netherlands)). Experiments were performed on paired sets (n=6) of airway and parenchymal 121 fibroblasts of passage 5/6. After reaching confluence, fibroblasts were cultured for 24h on 122 0.5% FBS culture medium before the stimulations started. Cells were washed with Ham's F12 123 culture medium (Lonza) without FBS and incubated with the appropriate stimulus, diluted in 124 0,5% FBS culture medium. Fluticasone (GSK, London, UK) was used in a concentration of 125
10
-8 M, TGFß (R&D systems, Abingdon, UK) was used in a concentration of 100 u/ml (= 3.1 126 ng/ml), and CSE was used in a concentration of 2.5%. CSE was prepared according to a 127 standardized protocol by bubbling the puffs of four 3R4F reference cigarettes (Kentucky 128 Optimal concentrations for the different stimuli and optimal time points for mRNA and 137 protein measurements of the different outcome parameters were determined in several test 138 experiments (data not shown). Based on these findings we decided to asses Smad3 139 phosphorylation at 1hour, mRNA levels at 24hours, and protein levels in cell lysates and 140 supernatants at 72hours. 141
142

RNA isolation and Real Time PCR 143
Fibroblast total RNA was isolated using the RNeasy mini kit (Qiagen). RNA quantity and 144 quality (OD 260/280) were determined by the Nanodrop D1000 (Nanodrop Technologies, 145
Wilmington, USA). Genomic DNA contamination was removed using Qiagen RNA-se free 146 The amount of Smad3, Smad7 and biglycan was detected in the 72hr samples using western 180 blot. Ten µg of total protein was run on 10% denaturating polyacrylamide gels and transferred 181 to nitrocellulose blots. The blots were blocked with 5% skim milk (Smad3 and 7) or 5% 182 FBS/PBS (biglycan) for 1 hour and incubated overnight with primary antibodies against 183 Smad3 (rabbit polyclonal, Zymed, Invitrogen, Breda, Netherlands), Smad7 (monoclonal, 184
Abnova, Heidelberg, Germany), and biglycan (goat polyclonal, R&D systems, Abingdon, 185 UK). After rinsing, the blots were incubated with peroxidase-labeled secondary antibodies for 186 1 hour. Staining was visualized using Supersignal chemiluminescent substrate (Pierce, Etten-187 Leur, Netherlands) and densities of the bands were determined by densitometry using 188 Quantity One software from Biorad . Beta Actin (rabbit-polyclonal, Abcam) was used as 189 loading control and Smad3, 7 and biglycan values were expressed as ratio compared to beta 190
Actin. 191 192
Statistical analysis 193
Differences between all groups, including different stimulations and airway and parenchymal 194 samples, were analyzed using the Kruskall-Wallis test. When significant, differences in basal 195 expression levels between airway and parenchymal samples were analyzed using the non-196 At basal conditions, Smad3 mRNA levels were lower in airway fibroblasts than parenchymal 227 fibroblasts (Fig. 1A) . Fluticasone did not affect Smad3 mRNA and protein levels in airway 228
fibroblasts, but it significantly reduced both Smad3 mRNA and protein levels in parenchymal 229 fibroblasts at basal conditions (Fig. 1A) . 230
TGFβ reduced Smad3 mRNA, and not protein expression in both airway and parenchymal 231 fibroblast. These effects were not affected by fluticasone treatment. 232 CSE increased Smad3 mRNA levels in airway fibroblasts, and this effect was inhibited by 233 fluticasone treatment. A similar inhibitory effect of fluticasone was present on Smad3 protein 234 levels in CSE treated airway and parenchymal (trend) fibroblasts. 235
TGFβ clearly increased Smad7 mRNA, and not protein expression in both airway and 236 parenchymal fibroblasts (Fig. 1B) . These effects were not affected by fluticasone. CSE had no 237 effect on Smad7 mRNA and protein expression. 238
TGFβ did not affect Smad3 phophorylation in airway fibroblasts, while it significantly 239 induced Smad3 phosphorylation in parenchymal fibroblasts, and this effect was not affected 240 by fluticasone (Fig. 1C) TGFβ increased biglycan mRNA and protein levels in both airway and parenchymal 258 fibroblasts (Fig. 3) . Fluticasone had no effect on TGFβ-induced biglycan protein levels in 259 airway fibroblasts, whereas it significantly reduced TGFβ-induced biglycan protein levels in 260 parenchymal fibroblasts. At basal conditions and in combination with CSE treatment, 261 fluticasone reduced biglycan protein levels in both airway and parenchymal fibroblasts. At basal conditions, procollagen 1 levels were lower in airway than parenchymal fibroblasts 266 (Fig. 4) . Fluticasone inhibited procollagen 1 protein production in parenchymal fibroblasts 267 under basal conditions and thus restored this difference. 268
TGFβ increased collagen1a2 mRNA expression in airway and parenchymal fibroblasts as 269 well as procollagen 1 protein levels in airway fibroblasts (Fig. 4) . Fluticasone had only 270 minimal effects on TGFβ-induced increases in collagen 1a2 mRNA and procollagen 1 protein 271 levels in airway fibroblasts, whereas it significantly reduced procollagen 1 protein levels in 272 parenchymal fibroblasts under all conditions. 273
Discussion 274
To find new and more individualized treatment strategies for patients with COPD, better 275 insight is needed into the abnormal smoke-induced tissue remodeling and repair process in 276 COPD lungs. This is particularly true for the differences between the airway and parenchymal 277 lung compartment given their putative role in progression of the disease. We hypothesized 278 that different lung fibroblast phenotypes exist and that steroids differentially affect fibroblasts 279 derived from airways and lung parenchyma. 280
Our findings demonstrated that airway and parenchymal fibroblasts from patients with severe 281 COPD differ in ECM production and response to TGFβ and that fluticasone differentially 282 affects airway and parenchymal fibroblasts. 283
At basal conditions, airway fibroblasts produced significantly lower levels of Smad3 mRNA 284 and procollagen-1 protein than parenchymal fibroblasts. Particularly after TGFβ stimulation 285 we found some essential differences between airway and parenchymal fibroblasts. In airway 286 fibroblasts, TGFβ significantly increased procollagen 1 production without affecting Smad3 287 phosphorylation, whereas in parenchymal fibroblasts TGFβ did not induce procollagen 288 production, while Smad3 phosphorylation was clearly increased. These observations may 289 suggest a less controlled collagen production in the airways of COPD patients, which could 290 favor airway remodeling together with a hampered Smad pathway-induced procollagen 291 production in the parenchyma, which fits with a lack of repair. Our findings regarding these 292 phenotypic differences between pulmonary fibroblasts from different lung compartments in 293 severe COPD are in line with previous studies in asthma patients (12, 24) , healthy donors and 294 cancer patients (17) and COPD (8). The observation that Smad3 mRNA levels and 295 procollagen 1 protein levels were both higher in parenchymal than airway fibroblasts at 296 baseline could be explained as a reflection of an ongoing attempt to repair parenchymal 297 damage. 298 A next question was whether an inhaled corticosteroid affects the TGFβ-Smad pathway and 299 ECM production in airway and parenchymal fibroblasts. Fluticasone, did not affect TGFβ-300 induced Smad pathway activation, as demonstrated by increased Smad7 mRNA expression 301 and Smad3 phosphorylation, whereas it clearly affected ECM production by pulmonary 302 fibroblasts. Fluticasone increased decorin mRNA and protein production by airway 303 fibroblasts, and the negative effect of TGFβ treatment on decorin production was restored to a 304 considerable extent. Additionally, fluticasone inhibited biglycan protein production in both 305 airway and parenchymal fibroblasts, albeit that TGFβ-induced increases in biglycan 306 production in airway fibroblasts were not inhibited by fluticasone. Interestingly, fluticasone 307 inhibited procollagen 1 production only in parenchymal fibroblasts, thereby restoring the 308 basal difference in procollagen 1 production between airway and parenchymal fibroblasts. 309
Our findings regarding the effects of fluticasone on ECM protein production in airway and 310 parenchymal fibroblasts are of particular interest, as the presence of these matrix proteins is 311 the end result of remodeling and repair processes in the lung. We have previously shown that 312 decorin expression is decreased around the airways of COPD patients (20, 23). Our current 313 observation that decorin production is stimulated by fluticasone in airway fibroblasts indicates 314 that steroids may still be capable of restoring decorin loss around the airways in patients with 315 very severe COPD. On the other hand, fluticasone inhibited the production of biglycan and 316 procollagen in parenchymal fibroblasts from these severe COPD patients, indicating that 317 steroids may inhibit the repair response particularly of fibroblasts that are located in 318 emphysematous areas of the lung that may need repair. 319
When comparing our findings with other studies investigating steroid effects on ECM 320 proteins in human lung fibroblasts, we found some overlapping but also different findings. 321
Goulet et al showed that fluticasone reduced total ECM and collagen deposition at basal 322 conditions in healthy peripheral lung fibroblasts (7). This is similar to what we found at basal 323 conditions in our parenchymal fibroblasts from severe COPD patients. However, in the 324 presence of FCS, which was used to mimic inflammatory conditions, Goulet et al showed that 325 ECM and collagen production was not reduced, but increased by fluticasone, which is clearly 326 different to the decrease we found in severe COPD. This discrepancy could signify that 327 parenchymal fibroblasts from healthy donors, as used by Goulet et al, still have the capability 328 to repair lung tissue by increasing their ECM production in inflammatory conditions, whilst 329 fibroblasts from our severe COPD patients do not have this capability. 330
Our findings regarding the effects of fluticasone on decorin and biglycan production are in 331 line with recent findings in asthma (19) . Todorova et al showed that budesonide could not 332 reverse TGFβ-induced increases in biglycan production by airway fibroblasts from 333
asthmatics. Furthermore, they demonstrated a reversal of the TGFβ-induced decrease in 334 decorin production by budesonide, also similar to our observations in severe COPD. 335
336
Our study provides a first clue about differences between fibroblasts from different lung 337 compartments in severe COPD and the differential effects of steroid treatment in this respect. 338
In summary, there appears to be uncontrolled collagen production in airway fibroblasts 339 whereas there is a diminished repair capacity by parenchymal fibroblasts in patients with 340 severe COPD. Our findings regarding the effects of steroids on the different compartments 341 indicate that steroids may have a beneficial effect on the airway compartment in severe COPD 342 patients, i.e. restoration of decorin loss around the airways, while the effects of steroids may 343 be detrimental on the parenchymal compartment as the tissue repair response is (further) 344 inhibited. The net balance between these effects has yet to be established. Clearly, this is the 345 first step towards better understanding of heterogeneity of COPD and inter-individual 346 differential effects of inhaled steroids in COPD. Our data suggest that established treatments 347 and novel treatments yet to be discovered should be investigated as to their effects on repair 348 capacity of cells in central and peripheral lung compartments separately. 
